HER2 in breast cancer - The focus on assessment methods;Kliniczne znaczenie zaburzeń HER2 w raku piersi z uwzglȩdnieniem metod ich oznaczania

Nowotwory

Volumn 53, Issue 1, 2003, Pages 68-73

  Krasińska, Liliana ^a   Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Breast cancer; HER2

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; HERCEPTEST; HERCEPTESTU; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CHEMOTHERAPY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CODE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; META ANALYSIS; ONCOGENE NEU; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TECHNIQUE; TUMOR GROWTH;

EID: 0037289515     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta 1994; 1198: 165-84.
2. Dowsett M, Cooke T, Ellis I i wsp. Assessment of HER2 status in breast cancer: why, when and how? EurJ Cancer 2000; 36: 170-76.
3. Slamon DJ, Clark GM, Wong SG i wsp. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
4. Rosen PP, Lesser ML, Arroyo CD i wsp. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 1995; 75: 1320-26.
5. Pauletti G, Dandekar S, Rong HM i wsp. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-64.
6. Slamon DJ, Godolphin W, Jones LA i wsp. Studies of the HER-2/neu prpto-oncogene in human breast and ovarian carcinoma. Science 1989; 244: 707-12.
7. Ross JS i Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
8. Seshardi R, Firgaira FA, Horsfall DJ i wsp. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993; 11: 1936-42.
9. Andrulis IL, Bull SB, Blackstein ME i wsp. neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998; 16: 1340-49.
10. Press MF, Bernastein L, Thomas PA i wsp. HER2/neu gene amplification characterized by florescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-904.
11. Gusterson BA, Gelber RD, Goldfish KN i wsp. Prognostic significance of c-erbB2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
12. Allred DC, Clark GM, Tandon AK i wsp. HER-2/neu in node-negative breast cancer: prognostic signifficance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
13. Menard S, Valagussa P, Pilotti S i wsp. Response to cyclophosphamide, methotrexate and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001; 19: 329-335.
14. Miles DW, Harris WH. Gillett CE i wsp. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999; 84: 354-59.
15. Paik S, Bryant J, Tan-Chiu E i wsp. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92: 1991-98.
16. Paik S, Bryant J, Park Ch i wsp. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-70.
17. Muss HB, Thor AD, Berry DA i wsp. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Eng J Med 1994; 330: 1260-66.
18. Thor AD, Berry DA, Budman DR i wsp. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-70.
19. Leitzel K, Teramoto Y, Konrad K i wsp. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-35.
20. Wright C, Nicholson S, Angus B i wsp. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-21.
21. Yamauchi H, O'Neil A, Gelman R i wsp. Prediction of response to anticstrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: 2518-25.
22. De Laurentis M, Arpino G, Massarelli E i wsp. A metaanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC). ASCO 2000; 19: Abstract 301.
23. Berry DA, Muss HB, Thor AD i wsp. HER-2/neu and p53 expression versus Tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18: 3471-79.
24. Knoop AS, Bentzen SM, Nielsen MM i wsp. Value of epidermal growth factor receptor, HER2, p53 and steroid receptors in predicting the efficacy of Tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19: 3376-84.
25. Bianco AR, De Laurentis M, Carlomabno C i wsp. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial. ASCO 2000, Abstract 289.
26. Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001; 37: 11-17.
27. Lebeau A, Deimling D, Kaltz C i wsp. HER-2/neu analysis in archival tissue samples of human breast cancer: comparisob of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-63
28. Harris LN, Liotcheva V, Broadwater G i wsp. Comparison of the methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19: 1698-1706.
29. Tubbs RR, Pettay JD, Roche PC i wsp. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-21.
30. Mass RD, Press M, Anderson S i wsp. Improved survival benefit from Herceptin (trastuzumab) inpatients selected by fluorescence in situ hybridization (FISH). ASCO 2001, Abstract 85.
31. Cobleigh M, Vogel C, Tripathy D i wsp. Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy. ECCO 11 - 2001; Abstract 701.
32. Ilersich L, Deschenes J, Tetu B i wsp. Cmetastatic breast cancer (MBC): an analysis of immuno-histochemistry (IHC), ft in-situ hybridization and Canadian Consensus Guidelines. ASCO 2001; Abstract 992.